Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders

Veronika Bachanova; Patrick H. Nachman

doi:10.1038/s41409-023-02084-3

Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	1175-1176
Number of pages	2
Journal	Bone marrow transplantation
Volume	58
Issue number	11
DOIs	https://doi.org/10.1038/s41409-023-02084-3
State	Published - Nov 2023

Bibliographical note

Funding Information:
VB has received research funding from Gamida Cell, Incyte, Citius, FATE Therapeutics. DSMB Board Member at Miltenyi; Advisory Board: Astra Zeneca, BeiGene, Allogene, Takeda, Caribou Bioscences, ADC. PHN: No conflicts of interest.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Publisher link

10.1038/s41409-023-02084-3

Find It

Find It at U of M Libraries

Cite this

@article{a279516483b84dd08c2e08a689bbc5ab,

title = "Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders",

author = "Veronika Bachanova and Nachman, \{Patrick H.\}",

note = "Funding Information: VB has received research funding from Gamida Cell, Incyte, Citius, FATE Therapeutics. DSMB Board Member at Miltenyi; Advisory Board: Astra Zeneca, BeiGene, Allogene, Takeda, Caribou Bioscences, ADC. PHN: No conflicts of interest. ",

year = "2023",

month = nov,

doi = "10.1038/s41409-023-02084-3",

language = "English (US)",

volume = "58",

pages = "1175--1176",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders

AU - Bachanova, Veronika

AU - Nachman, Patrick H.

N1 - Funding Information: VB has received research funding from Gamida Cell, Incyte, Citius, FATE Therapeutics. DSMB Board Member at Miltenyi; Advisory Board: Astra Zeneca, BeiGene, Allogene, Takeda, Caribou Bioscences, ADC. PHN: No conflicts of interest.

PY - 2023/11

Y1 - 2023/11

UR - https://www.scopus.com/pages/publications/85168372487

UR - https://www.scopus.com/pages/publications/85168372487#tab=citedBy

U2 - 10.1038/s41409-023-02084-3

DO - 10.1038/s41409-023-02084-3

M3 - Editorial

C2 - 37598289

AN - SCOPUS:85168372487

SN - 0268-3369

VL - 58

SP - 1175

EP - 1176

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 11

ER -

Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this